PMCB Insider Trading Activity and SEC Form 4 Filings
PMCB insider trading summary
Over the past 12 months, insiders at PharmaCyte Biotech, Inc. (PMCB) reported 6 open-market purchases worth $129K by 2 insiders and no sales on SEC Form 4. Net insider buying was $129K.
Latest PMCB insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 7, 2026 | Joshua Silverman | CEO and President | Buy | $33K (40,000 @ $0.83) |
| Jan 7, 2026 | Jonathan Schechter | Director | Buy | $17K (20,000 @ $0.84) |
| Jan 6, 2026 | Joshua Silverman | CEO and President | Buy | $24K (30,000 @ $0.79) |
| Jan 6, 2026 | Jonathan Schechter | Director | Buy | $16K (20,000 @ $0.79) |
| Jan 5, 2026 | Joshua Silverman | CEO and President | Buy | $23K (30,000 @ $0.78) |
| Jan 5, 2026 | Jonathan Schechter | Director | Buy | $16K (20,000 @ $0.78) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.